Atea Posts Q3 2026 Results; $200M Hercules Facility Extends Cash Runway to Mid-2028
AVIR sits 54% above its 52-week low of $2.87.
Summary
Atea reported a Q3 2026 net loss of $32.2 million and $191.2 million in cash, and said current resources plus its new Hercules credit facility fund operations into mid-2028. The next major event is C-FORWARD Phase 3 topline data in early 2027.
Key Events · Earnings and Guidance · AVIR
-
Q3 2026 Results Reported
Net loss of $32.2 million, or $0.40 per share, for the three months ended September 30, 2026, narrower than the $42.0 million loss a year earlier as R&D fell to $27.1 million from $38.3 million.
-
Cash Runway Extended to Mid-2028
Cash and investments stood at $191.2 million at September 30, 2026, down from $301.8 million at December 31, 2025; management says current resources plus the Hercules facility fund operations into mid-2028.
-
Hercules Facility Reiterated
The up-to-$200 million senior secured facility with Hercules Capital was drawn by $65 million at closing on November 6, 2026, with up to $135 million more available subject to milestones — debt financing rather than equity dilution.
-
C-FORWARD Readout Early 2027
The ex-North America Phase 3 trial is fully enrolled with more than 880 patients across 17 countries; topline results are expected in early 2027, supporting an NDA submission targeted for mid-2027.
Analysis · AVIR · Life Sciences
The balance sheet is the story here, not the pipeline. Atea's Q3 update largely recaps a pipeline that already cleared its biggest near-term hurdle: C-BEYOND hit its primary endpoint in July 2026, and the next real readout is C-FORWARD in early 2027. Cash fell to $191.2 million from $301.8 million at year-end 2025, and management says current resources plus the Hercules facility fund operations into mid-2028 — past the C-FORWARD readout and the targeted mid-2027 NDA filing. Because the $65 million drawn at closing is debt rather than equity, it extends runway without adding share dilution, though it does add a secured claim and milestone conditions on the remaining $135 million. R&D spend fell to $27.1 million from $38.3 million a year ago as HCV Phase 3 costs wind down.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVIR was trading at $4.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $353.7M. The 52-week trading range was $2.87 to $6.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.